Journal Title：Oncology-new York

Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.

盡管實驗室和臨床癌癥研究需要緊密聯系，但基礎層面的觀察結果往往與醫(yī)學應用相距甚遠。本期刊致力于加速實驗結果向臨床的轉化，并再次返回實驗室進行進一步研究。這項工作的根本目的是推進與臨床相關的癌癥知識，并改善惡性疾病的預防、診斷和治療效果。該期刊發(fā)表來自世界各地癌癥項目的重要臨床研究，以及重要的轉化實驗室發(fā)現、小型評論（邀請和提交）以及對腫瘤學領域不斷發(fā)展和有爭議的話題的深入討論。該期刊的一個獨特之處是新開設了一個欄目，重點關注快速同行評審和隨后發(fā)表 1 期和 2 期臨床癌癥試驗的簡短報告，目標是確保高質量的臨床癌癥研究迅速進入公共領域，無論試驗最終得出的療效或毒性結論如何。

Oncology-new York創(chuàng)刊于1987年，由UBM Medica Healthcare Publications出版商出版，收稿方向涵蓋腫瘤學 - 腫瘤學全領域，此期刊水平偏中等偏靠后，在所屬細分領域中專業(yè)影響力一般，過審相對較易，如果您文章質量佳，選擇此期刊，發(fā)表機率較高。平均審稿速度 較慢,6-12周 ，影響因子指數1.8，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。